What is the role of free PSA? Total PSA Range 2.5 to 4.0 ng/ml Age Range (Years) %Free PSA<60 (yrs)>=60 (yrs)All Ages <7849591 7-15254943 16-25102722.

Slides:

Advertisements

Similar presentations

1 Recruitment, Retention, Surgical and Medication Adherence Studies with African Americans: Lessons Learned Marvella E. Ford, Ph.D. Medical University.

Advertisements

PSA: Fact or Fiction The debate as it stands

Introduction The incidence of prostate cancer in Asians is lower compared to the Westerners in men with PSA

PSA and PROSTATE CANCER

HEALTHY PEOPLE. Aims  Interpret evidence about a screening programme and decide whether it is worthwhile – for individuals or groups  Demonstrate an.

PSA Testing William J Catalona MD Northwestern University.

RESULTS TITLE; Prospective randomized controlled trial of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening protocol.

What is the evidence of benefits of PSA screening for prostate cancer? Outpatient Medicine.

Prostate Cancer Screening: Con

A PRACTICAL GUIDE TO PSA SCREENING Kendall Itoku, MD St. Louis Urological Surgeons.

1 times table 2 times table 3 times table 4 times table 5 times table

EVIDENCE AND DEBATE SCREENING FOR PROSTATE CANCER.

Prostates & Pissing in the Wind. The Laytons Bob December 25, 1925 – May 9, 2002 Jack July 18, 1950 – August 22, 2011.

Prostate Cancer Screening 2012 Paul L. Crispen, MD Department of Surgery University of Kentucky.

M Ravanbod Medical oncologist Bushehr – 11/91 A 50 y/o white man comes for check up and wants to discuss about prostate cancer. Negative family history.

| Strathmore University Medical Centre Cancer Awareness Month October 2013.

Lecture Fourteen Biomedical Engineering for Global Health.

Prostate Screening in 2009: New Findings and New Questions Durado Brooks, MD, MPH Director, Prostate and Colorectal Cancer.

Prostate Cancer Screening. Google Search “Prostate Cancer” “Google Health” prostate cancer (OK) “Should All Men Be Screened for Prostate Cancer?” ABC.

5 Most Common Cancers. 1 in 2 men and 1 in 3 women in Australia will be diagnosed with cancer before the age of 85.

Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012.

PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition May 15, 2010.

J. Jacques Carter, MD, MPH Assistant Professor of Medicine Department of Medicine Harvard Medical School Beth Israel Deaconess Medical Center Boston, Massachusetts.

The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Fifth Annual African-American Prostate Cancer Disparity Summit September 24, 2009 Christine.

Use of Docetaxel based Chemotherapy for Castrate Resistant Prostate Cancer at LASUTH Ikeja Lagos Olufunmilade Akin Omisanjo.

Comprehensive Cancer Alliance for Idaho Idaho’s Hit List CCAI General Meeting November 14, 2007 Chris Johnson, MPH Cancer Data Registry of Idaho.

Il PSA nello screening del carcinoma della prostata PRO Franco Gaboardi Urologia Ospedale San Raffaele Turro Milano.

Table 1. Characteristics of patients and the results of the log-rank test of prognostic factors Median (range) No. of patients No. of CRPC Median progression.

$100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300.

Cancer “whiteboard” presentation ●Name of cancer (what type), where can it occur? ●Function of body part that it affects ●Causes (genetic, environmental…)?

Tables Learning Support

On the screens click on the number you think is the right answer. Three times tables Good luck!

FRENCH high-resolution studies - Breast cancer: 1990, 1997, 2003, 2010 ? - Colorectal cancer: 1990, 1995, 2000, 2005, 2010 ? - Prostate cancer: 1995,

United States Cancer Statistics 2002 Incidence and Mortality

Developed from information included in the AIHW report Cancer in Australia: in brief 2014 Highlights.

Prostate Cancer Screening Who needs it?... and who doesn’t. Presented by: Michael K. Yu, MD.

Cancer research in the Midland Region – the prostate and bowel cancer projects Ross Lawrenson Waikato Clinical School University of Auckland.

Preventative Care and Monitoring for Prostate Disease Joshua Broghammer, MD FACS Assistant Professor, Dept of Urology University of Kansas Medical Center.

PSA screening Cost Conscious Project Kristopher Huston January 2016.

Current Screening Recommendations and Practical Strategies to Refine Risk Assessment Following Initial Diagnosis Judd W. Moul, M.D. FACS Professor and.

PSA Consensus and The Prostate Cancer Risk Management Programme Karen Stalbow, Prostate Cancer UK Dr Ali Cooper, Prostate Cancer UK Annual Conference 2016.

Focal Magnetic Resonance Guided Intensity Focused Ultrasound Treatment of Low Risk Prostate Cancer: A Phase I Trial. Alexandr Nosov, Sergey Kanaev, Georg.

Copyright © 1998 American Medical Association. All rights reserved.

Volume 50, Issue 1, Pages (July 2006)

Volume 52, Issue 1, Pages (July 2007)

2017 USPSTF Draft Recommendations for Prostate Cancer Screening

Dr. John Jordan Dr. Stephen Pautler

Screening for Lung Cancer

Volume 71, Issue 1, Pages (January 2017)

Volume 63, Issue 4, Pages (April 2013)

by Jonathan N. Hofmann, Linda M. Liao, Michael N

Prostate Cancer Screening- Update

توزیع جغرافیایی مرگ به دلیل بدخیمی در کشور Age-standardized incidence rate of all cancers per 100 000 in female in Iran 2005–2006.

Volume 68, Issue 4, Pages (October 2015)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.

Volume 59, Issue 4, Pages (April 2011)

Cancer Screening Workshop A free one hour workshop for non clinical practice staff This session will: Provide participants with a good understanding.

Apoorva R. Vashi, M.D., Joseph E. Oesterling, M.D.

3 times tables.

6 times tables.

Volume 74, Issue 6, Pages (December 2018)

Volume 54, Issue 3, Pages (September 2008)

Stage, survival and delays in lung, colorectal, prostate and ovarian cancer: comparison between diagnostic routes by Richard D Neal, Victoria L Allgar,

Does PSA Testing Influence the Natural History of Prostate Cancer?

Volume 52, Issue 5, Pages (November 2007)

Overview of cancer genetics in the SMP1 cohort: lung cancer (A), breast cancer (B), colorectal adenocarcinoma (except mucinous subtype) (C), prostate cancer.

PSMA expression in pre- and posttreatment prostate carcinoma serum.

Presentation transcript:

What is the role of free PSA?

Total PSA Range 2.5 to 4.0 ng/ml Age Range (Years) %Free PSA<60 (yrs)>=60 (yrs)All Ages < >25276 Total PSA Range 2.5 to 4.0 ng/ml Age Range (Years)

Total PSA Range 4.01 to 10.0 ng/ml Age Range (Years) %Free PSA<60 (yrs)>=60 (yrs)All Ages < >25377

Total PSA Range10.01 to 20.0 ng/ml Age Range (Years) %Free PSA<60 (yrs)>=60 (yrs)All Ages < >25515 Total PSA Range10.01 to 20.0 ng/ml Age Range (Years)

Table 1 - Suggested upper limits of PSA for different age groups ² Age (years)Serum PSA (ng/ml)

Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

Cancer Screening Trial (PLCO)

ERSPC)